MRD monitoring of patients during follow-up in BM and PB
. | CR . | Relapse . | P . |
---|---|---|---|
Achievement of MRD− | |||
BM (n = 119) | |||
Yes, n (%) | 75 (89) | 9 (11) | |
No, n (%) | 9 (26) | 26 (74) | <.0001 |
PB (n = 112) | |||
Yes, n (%) | 74 (80) | 19 (20) | |
No, n (%) | 5 (26) | 14 (74) | <.0001 |
Repetitive MRD− | |||
BM (n = 119) | |||
Yes, n (%) | 51 (98) | 1 (2) | |
No, n (%) | 34 (51) | 33 (49) | <.0001 |
PB (n = 112) | |||
Yes, n (%) | 65 (96) | 3 (4) | |
No, n (%) | 14 (32) | 30 (68) | <.0001 |
. | CR . | Relapse . | P . |
---|---|---|---|
Achievement of MRD− | |||
BM (n = 119) | |||
Yes, n (%) | 75 (89) | 9 (11) | |
No, n (%) | 9 (26) | 26 (74) | <.0001 |
PB (n = 112) | |||
Yes, n (%) | 74 (80) | 19 (20) | |
No, n (%) | 5 (26) | 14 (74) | <.0001 |
Repetitive MRD− | |||
BM (n = 119) | |||
Yes, n (%) | 51 (98) | 1 (2) | |
No, n (%) | 34 (51) | 33 (49) | <.0001 |
PB (n = 112) | |||
Yes, n (%) | 65 (96) | 3 (4) | |
No, n (%) | 14 (32) | 30 (68) | <.0001 |